INGELHEIM, Germany--(BUSINESS WIRE)--For NON-U.S., UK & Canada Health Media Only
Boehringer Ingelheim today announced that more than 350,000 patients have already been prescribed Pradaxa® (dabigatran etexilate) for stroke prevention in non-valvular atrial fibrillation (AF) less than 10 months following its approval in the U.S., Canada and Japan.1,2,3 Latest data show that cardiologists have broadly adopted the breakthrough treatment in the U.S. and nine out of 10 that treat a majority of AF patients have prescribed it (n=14,019).4
